News & Events

Press Releases

October 27th, 2021

Agomab Therapeutics to Acquire Origo Biopharma

Agomab Therapeutics NV (‘Agomab’) announced today that it has entered into a definitive agreement under which it will acquire Origo Biopharma S.L., a Spanish clinical-stage biotechnology company developing organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway for the treatment of fibrosis-related disorders.
April 3rd, 2019

AgomAb Therapeutics Completes €21m Series A Financing

AgomAb Therapeutics N.V., a privately held Belgian biotherapeutics company developing agonistic antibodies for regeneration of damaged tissues, announces today that it has secured €21m in a Series A financing round from a strong international investor syndicate.

Loading...

End of content

No more pages to load

Looking to connect with us?

Jefferies London Healthcare Conference  
November 18-19, 2021

RBC Healthcare Private Company Conference  
December 15-16, 2021

Events

By continuing to use the site, you agree to the use of cookies. Privacy Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close